In the article titled "Power of nuclear weapon's EMP," Prof. Kim Sung-won of Pyongyang's elite tech school, Kim Chaek University of Technology, wrote that the North had confirmed the "massive ...
Under the terms of the agreement, Orion gains access to Abilita’s proprietary Enabled Membrane Protein (EMP™) technology for the discovery of novel antibody therapeutics to challenging GPCR (G ...
EMP-012 is under clinical development by Empirico and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) ...
Under the terms of the agreement, Orion gains access to Abilita’s proprietary Enabled Membrane Protein (EMP™) technology for the discovery of novel antibody therapeutics to challenging GPCR (G protein ...